Although research has shown benefits to using sodium zirconium cyclosilicate (SZC) to treat acute hyperkalemia (AHK), current treatment guidelines do not include SZC. Furthermore, SZC is not recommended for use as a single agent. Tara Parnacott and colleagues at Methodist University Hospital (MUH) in Memphis, Tennessee, assessed the use of SZC for AHK to determine whether changes should be made to the ordering plan. Their study results were presented during the National Kidney Foundation Spring Clinical Meetings 2024. ...
Nephrology Times
Nephrology Times delivers the latest news in kidney-related treatments and technologies with the goal of better informing care decisions and improving patient outcomes.
Advertisement
Latest News
Nocturnal hypertension is common in CKD, but it was unclear if renal denervation could lower nighttime blood pressure.
A patient may have normal creatinine and complements but still have highly active lupus nephritis requiring therapy.
Severe hyperkalemia after adrenalectomy is rare but can be managed medically with sodium zirconium cyclosilicate (SZC).
Sparsentan demonstrated meaningful benefits for preservation of kidney function compared with irbesartan over 2 years.
Dose adjustment requirements may differ between ESA-hyporesponsive and non–ESA-HR patients receiving daprodustat.
The FDA granted 510(k) clearance to TabloCart with prefiltration, an accessory for the Tablo Hemodialysis System.
Pooja Desai discussed a study examining short- vs long-term results of SZC therapy on hyperkalemia-related hospitalization.
In patients with chronic kidney disease, higher serum concentrations were associated with slower CKD progression.
A retrospective study examined whether SGLT2is are associated with cardiorenal benefits for patients with type 1 diabetes.
Patients with chronic kidney disease (CKD) may lack awareness of medication options for managing hyperkalemia.
Advertisement
Expert Interviews
In Print
Assessing recurrent gout risk, SARS-CoV-2 vaccine response during dialysis, plant-based diets with CKD, and more.
Special issue discusses racial inequity in living donor kidney transplant, teen BMI and CKD risk, and more
Conferences
The National Kidney Foundation's premier educational event designed for the interprofessional kidney health team
The annual scientific, educational, and networking meeting of the International Society of Nephrology
The American Society of Nephrology's annual meeting to highlight the latest scientific and medical advances in the field
The joint annual meeting of the American Society of Transplantation and the American Society of Transplant Surgeons
Podcasts
Will sparsentan prove a winner for patients with FSGS, or are we doomed to forever treat them with Acthar Gel?
We've all been guilted into ordering inpatient blood pressure meds. Tim Anderson, MD, asks, "Why?"
Review Dr. Burton Rose's writings on treatment options for hypovolemic states and hypovolemic shock.
Expert Columns
Medicare Advantage plans are posing significant operational and financial hurdles for dialysis programs.
APRIL has emerged as a critical factor in the pathogenesis of IgAN and is the focus of several clinical development programs.
The benefit-risk ratio and considerations about unmet need are worth considering.
The choice of a billing solution, often made under the guise of cost savings, requires a thoughtful approach.
The new base rate for CY 2024 is set at $271.02, which is a 2% increase from CY 2023.
SGLT2i therapy is contraindicated in patients with type 1 diabetes mellitus (T1DM) who have CKD.
Advertisement
Advertisement
Nephrology Times Chair
Ajay K. Singh, MBBS, FRCP, MBASenior Nephrologist, Brigham and Women’s Hospital | Senior Associate Dean, Harvard Medical School
Editorial Board
Mohamed G. Atta, MD, MPHProfessor of Medicine, Johns Hopkins School of Medicine
Timothy E. Bunchman, MDProfessor and Director, Pediatric Nephrology, Transplantation, and Rheumatology, Children’s Hospital of Richmond at VCU
Suphamai Bunnapradist, MD, MSProfessor of Medicine, David Geffen School of Medicine at UCLA | Research Director, Kidney Transplant Program, UCLA
Fernando C. Fervenza, MD, PhDProfessor of Medicine, Division of Nephrology and Hypertension, Mayo Clinic
Kenneth A. Liss, DOPartner, Hypertension and Nephrology Association, Eatontown, NJ
Joel M. Topf, MD, FACPAssistant Clinical Professor of Medicine, Oakland University William Beaumont School of Medicine
